Retail sales of botulinum toxin products in Russia (including specialized retail, pharmacies, and the clinical segment) reached RUB 13.1 billion in January–October 2025 (at retail prices, including VAT). Over this period, a total of 142.1 million activity units (AU) of botulinum toxins were sold, or approximately 83.7 million equivalent activity units* (taking into account dose equivalence recalculation for Dysport). According to the Audit of Retail Pharmaceutical Sales in Russia (total sell out) database of analytical company RNC Pharma, value sales growth compared with January–October 2024 amounted to 47.3%, while volume growth indicators were at comparable levels: +38.6% in activity units and +44.6% in equivalent activity units.

The distribution structure of the retail market for botulinum toxin products is highly complex and includes three main channels. The most significant role is played by specialized outlets—retail divisions of distributors focused on the sale of aesthetic and cosmetology products. In January–October 2025, these outlets accounted for 43.6% of all equivalent botulinum toxin units sold, with their primary customers being private-practice cosmetologists. The second most important channel is pharmacies, which accounted for 25.5% of unit sales, while a nearly identical share (24.8%) was generated by the clinical segment, where botulinum toxin products are administered as part of cosmetic procedures. Notably, the role of pharmacies has been steadily declining: over the past three years, their share has decreased by 15 percentage points, including a 7.5 percentage point decline in 2025 alone. The online channel plays a minimal role in the segment, accounting for just 6.1% of sales.

The absolute leader among brands in terms of activity units sold is Dysport (Ipsen). In January–October 2025, retail sales of this product reached 87.6 million activity units. However, given that the effective dose of Dysport relative to other botulinum toxins is approximately 3 to 1, the equivalent number of units amounts to around 29.2 million. Sales of the Russian product Relatox (Natsimbio) totaled 31.3 million activity units over the period, corresponding to approximately 37.4% of total sales volume in equivalent activity units. Notably, Relatox demonstrated strong growth dynamics: compared with January–October 2024, retail sales increased by 59%, while Dysport recorded growth of 31%.

Sales of the Russian product Myotox (Innopharm) showed comparable growth rates, increasing by 35% year on year. The product is manufactured at the facilities of the M.P. Chumakov Institute of Poliomyelitis. A high growth rate was also demonstrated by the Korean product Novacutan-BTA (Institute of Beauty Fijie), with sales up 58%. The absolute leader in terms of growth in 2025, however, was Xeomin (Merz Pharma), with an 80% increase in sales.

Botox (Allergan) continues to play a noticeable role in the market. Despite the fact that official supplies of the product were discontinued in 2022, approximately 537 thousand activity units were sold in Russian retail during the first ten months of 2025. Nevertheless, sales volumes declined slightly over the past year, decreasing by 2%.

Table. TOP botulinum toxin brands by sales volume on the Russian retail market (including specialized retail, pharmacies, and the clinical segment), January–October 2025, in physical terms (activity units and equivalent activity units)

* Equivalent activity units take into account that the effective therapeutic dose of Dysport for aesthetic indications is approximately three times higher than that of other botulinum toxin products.